Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about BIIB, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Nusinersen FDA approved Dec 2016 · Spinraza |
Muscular Atrophy, Spinal | Phase 4 · NCT04488133 | Completed |
| Tofersen FDA approved Apr 2023 · Qalsody |
Amyotrophic Lateral Sclerosis | Phase 4 · NCT07223723 | Active not recruiting |
| Peginterferon Beta-1A FDA approved Aug 2014 · Plegridy |
Multiple Sclerosis, Relapsing-Remitting | Phase 3 · NCT03958877 | Active not recruiting |
| Interferon Beta-1A FDA approved May 1996 · Avonex |
Multiple Sclerosis, Relapsing-Remitting | Phase 3 · NCT03958877 | Active not recruiting |
| Omaveloxolone FDA approved Feb 2023 · Skyclarys |
Friedreich Ataxia | Phase 3 · NCT06953583 | Active not recruiting |
| Natalizumab FDA approved Nov 2004 · Tysabri |
Multiple Sclerosis | N/A · NCT05658497 | Recruiting |
| Zuranolone FDA approved Aug 2023 · Zurzuvae |
Postpartum Depression | N/A · NCT07398469 | Recruiting |
| Diroximel Fumarate FDA approved Oct 2019 · Vumerity |
Multiple Sclerosis | N/A · NCT05658497 | Recruiting |
| Dimethyl Fumarate FDA approved Mar 2013 · Tecfidera |
Multiple Sclerosis | N/A · NCT05658497 | Recruiting |
| Litifilimab | Subacute Cutaneous Lupus Erythematosus | Phase 3 · NCT06044337 | Enrolling by invitation |
| Lecanemab SC | Early Alzheimer's Disease | Phase 3 · NCT03887455 | Active not recruiting |
| Lecanemab IV | Early Alzheimer's Disease | Phase 3 · NCT03887455 | Active not recruiting |
| Felzartamab | Immunoglobulin A Nephropathy (IgAN) | Phase 3 · NCT06935357 | Recruiting |
| Salanersen | Muscular Atrophy, Spinal | Phase 3 · NCT07444450 | Recruiting |
| Diranersen | Mild Cognitive Impairment Due to Alzheimer's Disease | Phase 2 · NCT05399888 | Active not recruiting |
| BIIB147 | Amyotrophic Lateral Sclerosis | Phase 1/2 · NCT07855211 | Recruiting |
Also used in these trials (approved or third-party drugs, not BIIB's own candidates): Tacrolimus Extended-Release, Ponesimod, Siponimod, Ofatumumab, Ocrelizumab, Glatiramer Acetate, Fingolimod Hydrochloride, Interferon Beta-1B, Alemtuzumab.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
BIIB holds $1.3B in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.
Dilution pressure: 0 · Low
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when BIIB files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| FMR LLC | Institution (13G, 5%+) | 18,294,524 | 12.38% | 2026-06-30 |
| Blackrock Inc. | Institution (13F) | 16,089,189 | 10.88% | 2026-09-30 |
| Primecap Management Company | Institution (13F) | 15,197,022 | 10.28% | 2026-09-30 |
| Vanguard Capital Management | Institution (13G, 5%+) | 10,989,562 | 7.43% | 2026-03-31 |
| STATE STREET CORPORATION | Institution (13G, 5%+) | 7,570,589 | 5.12% | 2026-09-30 |
| Vanguard Portfolio Management LLC | Institution (13F) | 6,572,163 | 4.45% | 2026-09-30 |
| Geode Capital Management, LLC | Institution (13F) | 4,507,404 | 3.05% | 2026-09-30 |
| Wellington Management Group, LLP | Institution (13F) | 3,458,781 | 2.34% | 2026-09-30 |
| Morgan Stanley | Institution (13F) | 2,506,411 | 1.70% | 2026-09-30 |
| Susan H Alexander EVP Chief Legal Officer · +20,224 options |
Insider | 61,889 | 0.04% | 2026-02-06 |
| Caroline Dorsa Director |
Insider | 31,002 | 0.02% | 2025-06-17 |
| Christopher Viehbacher President and CEO, Director · +77,931 options |
Insider | 29,924 | 0.02% | 2026-02-06 |
Share count 147,820,223 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-10-30 filed 2026-11-02 |
Grogan Jane |
Option exercise (M) | 695 | – | 4,753 |
| 2026-10-30 filed 2026-11-02 |
Grogan Jane |
Tax withholding (F) | 345 | $253.62 | 4,408 |
| 2026-10-30 filed 2026-11-02 |
Grogan Jane |
Option exercise (M) | 695 | – | – |
| 2026-10-02 filed 2026-10-05 |
Godbout Sean |
Option exercise (M) | 27 | – | 1,467 |
| 2026-10-02 filed 2026-10-05 |
Godbout Sean |
Tax withholding (F) | 8 | $219.88 | 1,459 |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
| Date | Drug | Type | Run-up 30d | Decision 1d | After 5d |
|---|---|---|---|---|---|
| 2026-05-24 | — | NDA | +3.1% | -0.4% | -0.8% |
| 2026-04-03 | LEQEMBI® IQLIK™ (lecanemab-irmb) | NDA | -6.6% | -2.8% | -2.5% |
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BIIB and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →